Francisco Javier Gil-Bea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francisco Javier Gil-Bea has a total of 262 co-authors. Here are the top co-authors by number of shared publications:
- Maria Javier Ramirez
Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain
23 shared publications - Angel Cedazo-Minguez
Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden
13 shared publications - Gorka Gerenu
Neurosciences Area, Biogipuzkoa Health Research Institute, Donostia/San Sebastián 20014, Spain
12 shared publications Beatriz Marcos
6 shared publicationsBengt Winblad
Department of Neurobiology, KI‐Alzheimer's Disease Research Center, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
6 shared publications- Maite Solas
Department of Pharmaceutical Sciences, University of Navarra, Pamplona, Spain
6 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wiley in Advanced Science
Membrane‐Targeted Nanoparticles for Neuronal Photomodulation
Selective targeting of nanoparticles to the neuronal interface is central for the tailored development of precision neurotechnologies. Here, we report the targeting of gold bipyramids, as a model nanomaterial, on the membrane of primary neurons using a bioorthogonal approach. In a two‐step process, linker molecules anchor to receptors that expose trans‐cyclooctene, which forms a covalent bond with the tetrazine functional group on nanoparticles, leading to the retention of hundreds of nanoparticles per cell. Selective labeling of neuronal membranes with plasmonic nanoparticles via a bioorthogonal strategy enabled inhibition of neuronal activity through photothermal effects under NIR laser irradiation in synchronized cell cultures. The linker and/or nanoparticles alone have a negligible effect on neuromodulation. Nanoparticle retention at the membrane is rapid, requiring only one hour of total incubation, with no cytotoxic effect. These results expand the repertoire of light‐activated nanomaterials for non‐invasive neuromodulation.
- 1 November 2026
- Published by Wiley in Advanced Science
Open AccessMembrane‐Targeted Nanoparticles for Neuronal Photomodulation
Selective targeting of nanoparticles to the neuronal interface is central for the tailored development of precision neurotechnologies. Here, we report the targeting of gold bipyramids, as a model nanomaterial, on the membrane of primary neurons using a bioorthogonal approach. In a two‐step process, linker molecules anchor to receptors that expose trans‐cyclooctene, which forms a covalent bond with the tetrazine functional group on nanoparticles, leading to the retention of hundreds of nanoparticles per cell. Selective labeling of neuronal membranes with plasmonic nanoparticles via a bioorthogonal strategy enabled inhibition of neuronal activity through photothermal effects under NIR laser irradiation in synchronized cell cultures. The linker and/or nanoparticles alone have a negligible effect on neuromodulation. Nanoparticle retention at the membrane is rapid, requiring only one hour of total incubation, with no cytotoxic effect. These results expand the repertoire of light‐activated nanomaterials for non‐invasive neuromodulation.
- Open Access
Criticality-related dynamics accompany long-term functional decline in primary cortical MEA cultures
Primary cortical neuron cultures are widely used to study network development and decline, but their long-term electrophysiological trajectories are poorly characterized. We used multi-electrode arrays to longitudinally monitor Wistar rat cortical cultures for up to ∼730 days in vitro (DIV), combining activity measures with survival analysis and criticality metrics. Wells shared an early developmental phase, with mean firing rate peaking at 12–14 Hz around DIV 100–150, before diverging into two phenotypes: early-death wells, showing progressive loss of burst organization, longer inter-burst intervals, shorter bursts, and steep declines in active-electrode recruitment; and long-survival wells, which sustained organized bursting and measurable activity well beyond DIV 400, in some cases past DIV 700. Cox proportional-hazards modeling with FDR correction across thirteen candidate features identified burst duration, inter-burst interval, synchrony, mean firing rate, branching ratio, and Kappa index as significant predictors of time to network failure. Criticality metrics offered the most mechanistic insight: in early-death wells, branching ratio declined toward zero and Kappa index rose toward its upper bound as networks approached silencing. Beyond their average levels, the rate of change of branching ratio and Kappa index over recordings was the strongest correlate of survival time among all criticality metrics. Neuronal avalanche size and duration exponents and their scaling relation, remained consistent with scale-free dynamics in both phenotypes while networks were active, though avalanche occurrence rate declined progressively in early-death wells without reaching significance as an independent predictor. These results show that long-term network survival is not determined by firing rate alone, but by preserved burst organization, sustained electrode recruitment and near-critical propagation dynamics. This work offers one of the longest electrophysiological characterizations of rodent cortical cultures to date and identifies criticality-based metrics as promising tools for predicting network decline and evaluating interventions to preserve long-term neuronal function. Author summary: Cultures of neurons grown on multi-electrode arrays let researchers record the electrical activity of developing brain-like networks over time. We recorded electrical activity from rat cortical neuron cultures continuously for up to nearly two years, one of the longest such studies to date. We found that networks followed one of two distinct trajectories: about a third of the networks lost their organized firing patterns within the first year in culture, while the rest sustained coordinated activity well beyond that point, in some cases for close to two years. Firing rate alone (how often neurons fired) did not reliably distinguish these two groups. What did was the structure of that activity: how firing was organized into bursts, how synchronized different regions of the network remained, and how efficiently electrical signals propagated across the network, a property linked to networks operating near a so-called “critical” state, thought to support efficient information processing in the brain. These features changed months before other, more obvious signs of decline appeared, in some cases within the first three to ten months in culture. We propose that tracking this kind of network-level organization, rather than raw activity levels, offers a more sensitive way to study neuronal ageing and to test whether experimental treatments genuinely protect brain network function.
Open AccessCriticality-related dynamics accompany long-term functional decline in primary cortical MEA cultures
Primary cortical neuron cultures are widely used to study network development and decline, but their long-term electrophysiological trajectories are poorly characterized. We used multi-electrode arrays to longitudinally monitor Wistar rat cortical cultures for up to ∼730 days in vitro (DIV), combining activity measures with survival analysis and criticality metrics. Wells shared an early developmental phase, with mean firing rate peaking at 12–14 Hz around DIV 100–150, before diverging into two phenotypes: early-death wells, showing progressive loss of burst organization, longer inter-burst intervals, shorter bursts, and steep declines in active-electrode recruitment; and long-survival wells, which sustained organized bursting and measurable activity well beyond DIV 400, in some cases past DIV 700. Cox proportional-hazards modeling with FDR correction across thirteen candidate features identified burst duration, inter-burst interval, synchrony, mean firing rate, branching ratio, and Kappa index as significant predictors of time to network failure. Criticality metrics offered the most mechanistic insight: in early-death wells, branching ratio declined toward zero and Kappa index rose toward its upper bound as networks approached silencing. Beyond their average levels, the rate of change of branching ratio and Kappa index over recordings was the strongest correlate of survival time among all criticality metrics. Neuronal avalanche size and duration exponents and their scaling relation, remained consistent with scale-free dynamics in both phenotypes while networks were active, though avalanche occurrence rate declined progressively in early-death wells without reaching significance as an independent predictor. These results show that long-term network survival is not determined by firing rate alone, but by preserved burst organization, sustained electrode recruitment and near-critical propagation dynamics. This work offers one of the longest electrophysiological characterizations of rodent cortical cultures to date and identifies criticality-based metrics as promising tools for predicting network decline and evaluating interventions to preserve long-term neuronal function. Author summary: Cultures of neurons grown on multi-electrode arrays let researchers record the electrical activity of developing brain-like networks over time. We recorded electrical activity from rat cortical neuron cultures continuously for up to nearly two years, one of the longest such studies to date. We found that networks followed one of two distinct trajectories: about a third of the networks lost their organized firing patterns within the first year in culture, while the rest sustained coordinated activity well beyond that point, in some cases for close to two years. Firing rate alone (how often neurons fired) did not reliably distinguish these two groups. What did was the structure of that activity: how firing was organized into bursts, how synchronized different regions of the network remained, and how efficiently electrical signals propagated across the network, a property linked to networks operating near a so-called “critical” state, thought to support efficient information processing in the brain. These features changed months before other, more obvious signs of decline appeared, in some cases within the first three to ten months in culture. We propose that tracking this kind of network-level organization, rather than raw activity levels, offers a more sensitive way to study neuronal ageing and to test whether experimental treatments genuinely protect brain network function.
- Open Access
Modulation of retroviral capsid assembly halts ARC-mediated TDP-43 intercellular spreading
Intercellular propagation of pathological TDP-43 drives the progression of ALS and FTD, yet the mechanisms enabling transmission remain elusive. Here, we demonstrate that Activity-regulated cytoskeleton associated protein (ARC/Arg3.1) is pathologically subverted to act as a retroviral-like capsid vehicle for TDP-43 spreading. In a Drosophila model, we reveal that massive Arc1 upregulation drives glia-to-neuron TDP-43 seeding, while its genetic ablation halts pathological transfer, improves motor function, and extends survival. In parallel human cellular models, stress-induced ARC colocalizes with TDP-43 to orchestrate its intercellular transmission. Guided by ARC’s capsid architecture, we reproposed Lenacapavir, an FDA-approved HIV-1 capsid modulator, as a stable binder of ARC/Arg3.1 capsid interfaces. Lenacapavir treatment effectively blocks TDP-43 propagation in vitro and rescues disease phenotypes in vivo. Our findings establish ARC as a conserved vehicle for pathological protein transmission and deliver an immediately translatable pharmacological strategy to arrest disease progression in ALS and FTD.
Open AccessModulation of retroviral capsid assembly halts ARC-mediated TDP-43 intercellular spreading
Intercellular propagation of pathological TDP-43 drives the progression of ALS and FTD, yet the mechanisms enabling transmission remain elusive. Here, we demonstrate that Activity-regulated cytoskeleton associated protein (ARC/Arg3.1) is pathologically subverted to act as a retroviral-like capsid vehicle for TDP-43 spreading. In a Drosophila model, we reveal that massive Arc1 upregulation drives glia-to-neuron TDP-43 seeding, while its genetic ablation halts pathological transfer, improves motor function, and extends survival. In parallel human cellular models, stress-induced ARC colocalizes with TDP-43 to orchestrate its intercellular transmission. Guided by ARC’s capsid architecture, we reproposed Lenacapavir, an FDA-approved HIV-1 capsid modulator, as a stable binder of ARC/Arg3.1 capsid interfaces. Lenacapavir treatment effectively blocks TDP-43 propagation in vitro and rescues disease phenotypes in vivo. Our findings establish ARC as a conserved vehicle for pathological protein transmission and deliver an immediately translatable pharmacological strategy to arrest disease progression in ALS and FTD.
- Open Access
Systemic ELOVL6 activity predicts survival and represents a modifiable target of ALS
Background: Amyotrophic lateral sclerosis (ALS) is characterized by profound metabolic reprogramming, yet the lack of biomarkers for specific druggable targets remains a major hurdle for precision medicine. We hypothesized that peripheral lipid biosynthetic signatures could serve as both prognostic indicators and a roadmap for identifying novel disease-modifying targets. Methods: We assessed serum fatty acid (FA) metabolic pathways in two independent longitudinal cohorts (n = 37 and n = 38) using high-dimensional CoxBoost modeling. Primary outcomes were survival and functional staging milestones, including non-invasive ventilation and gastrostomy. The biological relevance of the identified candidate was further assessed through correlation with plasma neurofilament light-chain (NfL) levels. Causality and therapeutic potential were validated in Drosophila melanogaster models of TDP-43 proteinopathy via genetic ablation and pharmacological inhibition. Results: Our multi-parametric model, comprising two clinical variables and the estimated ELOVL6 (elongation of very long-chain fatty acids protein 6) activity, demonstrated robust prognostic accuracy (Uno’s C 0.69) across both cohorts; ELOVL6 activity served as a strong independent predictor of mortality and functional decline. Notably, high ELOVL6 activity significantly correlated with elevated plasma NfL levels (p < 0.01), linking peripheral elongation imbalances to central axonal damage. In Drosophila, ELOVL6 overactivation was identified as a conserved pathological consequence of TDP-43 dysfunction, characterized by an increased C18:0/C16:0 ratio in both loss-of-function and gain-of-function models. Inhibition of ELOVL6, either genetically or pharmacologically, rescued neuromuscular junction integrity, prolonged survival, and significantly reduced pathological TDP-43 phosphorylation in glial models. Conclusion: These findings position ELOVL6 as a promising modifiable metabolic node with potential for disease-modifying intervention in ALS. Beyond its potential utility for identifying high-risk metabolic profiles and assisting in prognostic counseling, ELOVL6 bridges systemic lipid dysregulation with TDP-43 proteinopathy. Targeting this pathway offers a dual opportunity: as a biological marker to supplement clinical staging and as a druggable enzymatic target to ameliorate motor neuron degeneration. HIGHLIGHTS: Systemic ELOVL6 activity is a robust independent predictor of ALS survival. High ELOVL6 levels correlate with plasma NfL and functional decline. Inhibition of ELOVL6 rescues NMJ integrity and survival in Drosophila models. Pharmacological targeting of ELOVL6 reduces glial TDP-43 phosphorylation. ELOVL6 represents a druggable metabolic node linking lipids to proteinopathy.
Open AccessSystemic ELOVL6 activity predicts survival and represents a modifiable target of ALS
Background: Amyotrophic lateral sclerosis (ALS) is characterized by profound metabolic reprogramming, yet the lack of biomarkers for specific druggable targets remains a major hurdle for precision medicine. We hypothesized that peripheral lipid biosynthetic signatures could serve as both prognostic indicators and a roadmap for identifying novel disease-modifying targets. Methods: We assessed serum fatty acid (FA) metabolic pathways in two independent longitudinal cohorts (n = 37 and n = 38) using high-dimensional CoxBoost modeling. Primary outcomes were survival and functional staging milestones, including non-invasive ventilation and gastrostomy. The biological relevance of the identified candidate was further assessed through correlation with plasma neurofilament light-chain (NfL) levels. Causality and therapeutic potential were validated in Drosophila melanogaster models of TDP-43 proteinopathy via genetic ablation and pharmacological inhibition. Results: Our multi-parametric model, comprising two clinical variables and the estimated ELOVL6 (elongation of very long-chain fatty acids protein 6) activity, demonstrated robust prognostic accuracy (Uno’s C 0.69) across both cohorts; ELOVL6 activity served as a strong independent predictor of mortality and functional decline. Notably, high ELOVL6 activity significantly correlated with elevated plasma NfL levels (p < 0.01), linking peripheral elongation imbalances to central axonal damage. In Drosophila, ELOVL6 overactivation was identified as a conserved pathological consequence of TDP-43 dysfunction, characterized by an increased C18:0/C16:0 ratio in both loss-of-function and gain-of-function models. Inhibition of ELOVL6, either genetically or pharmacologically, rescued neuromuscular junction integrity, prolonged survival, and significantly reduced pathological TDP-43 phosphorylation in glial models. Conclusion: These findings position ELOVL6 as a promising modifiable metabolic node with potential for disease-modifying intervention in ALS. Beyond its potential utility for identifying high-risk metabolic profiles and assisting in prognostic counseling, ELOVL6 bridges systemic lipid dysregulation with TDP-43 proteinopathy. Targeting this pathway offers a dual opportunity: as a biological marker to supplement clinical staging and as a druggable enzymatic target to ameliorate motor neuron degeneration. HIGHLIGHTS: Systemic ELOVL6 activity is a robust independent predictor of ALS survival. High ELOVL6 levels correlate with plasma NfL and functional decline. Inhibition of ELOVL6 rescues NMJ integrity and survival in Drosophila models. Pharmacological targeting of ELOVL6 reduces glial TDP-43 phosphorylation. ELOVL6 represents a druggable metabolic node linking lipids to proteinopathy.
- Open Access
- 23 April 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (8)
Mitochondrial DNA replication is regulated by endoplasmic reticulum-mitochondrial contact sites, the mitochondrial calcium uniporter, and manganese
Mitochondrial DNA replication occurs at contact sites between the endoplasmic reticulum (ER) and mitochondria (ERMCS). Beyond the known role of the tubular ER protein RTN4, the factors regulating this process are poorly defined. Here, we show that repressing the ER protein ERLIN2 in human fibroblasts depletes ER–mitochondrial contact sites and inhibits mitochondrial DNA replication, as does silencing RTN4 or the ER–mitochondrial tether GRP75. GRP75 or RTN4 scarcity also decreases the level of the mitochondrial calcium uniporter (MCU), whose inhibition blocks mitochondrial DNA synthesis. Because ERMCS depletion did not diminish mitochondrial calcium, and MCU complex can transport manganese, we tested whether manganese could bypass these defects. Manganese supplementation restored mitochondrial DNA replication in cells lacking ERMCS or with inhibited MCU, identifying manganese as a critical mediator. We then considered mitochondrial transcription as a potential manganese target, since it provides both transcripts for gene expression and primers for DNA replication. In vitro, manganese inhibits transcription re-start and stimulates RNA synthesis at the light-strand origin of replication. These findings support a model in which ER–mitochondrial contact sites, in conjunction with MCU, deliver manganese from the ER to mitochondria to promote DNA replication, potentially by modulating mitochondrial RNA polymerase activity.
- 23 April 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (8)
Open AccessMitochondrial DNA replication is regulated by endoplasmic reticulum-mitochondrial contact sites, the mitochondrial calcium uniporter, and manganese
Mitochondrial DNA replication occurs at contact sites between the endoplasmic reticulum (ER) and mitochondria (ERMCS). Beyond the known role of the tubular ER protein RTN4, the factors regulating this process are poorly defined. Here, we show that repressing the ER protein ERLIN2 in human fibroblasts depletes ER–mitochondrial contact sites and inhibits mitochondrial DNA replication, as does silencing RTN4 or the ER–mitochondrial tether GRP75. GRP75 or RTN4 scarcity also decreases the level of the mitochondrial calcium uniporter (MCU), whose inhibition blocks mitochondrial DNA synthesis. Because ERMCS depletion did not diminish mitochondrial calcium, and MCU complex can transport manganese, we tested whether manganese could bypass these defects. Manganese supplementation restored mitochondrial DNA replication in cells lacking ERMCS or with inhibited MCU, identifying manganese as a critical mediator. We then considered mitochondrial transcription as a potential manganese target, since it provides both transcripts for gene expression and primers for DNA replication. In vitro, manganese inhibits transcription re-start and stimulates RNA synthesis at the light-strand origin of replication. These findings support a model in which ER–mitochondrial contact sites, in conjunction with MCU, deliver manganese from the ER to mitochondria to promote DNA replication, potentially by modulating mitochondrial RNA polymerase activity.
- Open Access
Mitochondria and Lipid Defects in Hereditary Progranulin-Related Frontotemporal Dementia
Frontotemporal dementia (FTD) is a neurodegenerative disorder predominantly affecting individuals under 65 years of age, characterized by significant behavioral and language disabilities. Despite extensive research efforts, effective treatments for FTD remain elusive. Familial cases of FTD have been linked to genetic mutations in several key genes, among these, mutations in granulin (GRN) account for 5–20% of cases, leading to haploinsufficiency of progranulin (PGRN), a multifunctional glycoprotein. This study investigates the cellular pathology associated with GRN insufficiency by using fibroblasts derived from FTD patients carrying the c.709-1G>A GRN mutation (FTD-GRN). These fibroblasts exhibited pathological hallmarks of FTD, including lysosomes, autophagosomes, and lipofuscin accumulation, mirroring observations in affected patient tissues. Notably, we report mitochondrial abnormalities, characterized by mitochondrial swelling which is associated with decreased mitochondrial respiration, and lipid droplet accumulation, reflecting altered lipid metabolism. Experimental supplementation with recombinant human progranulin (rhPGRN) was associated with recovery of lysosomal acidification and attenuation of mitochondrial and lipid abnormalities in vitro. This study reveals that GRN haploinsufficiency induces mitochondrial and lipid dysfunctions, suggesting that these pathways may contribute to FTD-GRN pathogenesis and could be of interest for therapeutic development.
Open AccessMitochondria and Lipid Defects in Hereditary Progranulin-Related Frontotemporal Dementia
Frontotemporal dementia (FTD) is a neurodegenerative disorder predominantly affecting individuals under 65 years of age, characterized by significant behavioral and language disabilities. Despite extensive research efforts, effective treatments for FTD remain elusive. Familial cases of FTD have been linked to genetic mutations in several key genes, among these, mutations in granulin (GRN) account for 5–20% of cases, leading to haploinsufficiency of progranulin (PGRN), a multifunctional glycoprotein. This study investigates the cellular pathology associated with GRN insufficiency by using fibroblasts derived from FTD patients carrying the c.709-1G>A GRN mutation (FTD-GRN). These fibroblasts exhibited pathological hallmarks of FTD, including lysosomes, autophagosomes, and lipofuscin accumulation, mirroring observations in affected patient tissues. Notably, we report mitochondrial abnormalities, characterized by mitochondrial swelling which is associated with decreased mitochondrial respiration, and lipid droplet accumulation, reflecting altered lipid metabolism. Experimental supplementation with recombinant human progranulin (rhPGRN) was associated with recovery of lysosomal acidification and attenuation of mitochondrial and lipid abnormalities in vitro. This study reveals that GRN haploinsufficiency induces mitochondrial and lipid dysfunctions, suggesting that these pathways may contribute to FTD-GRN pathogenesis and could be of interest for therapeutic development.
- Open Access
Computational Analysis of ELOVL6 Structure and Inhibition for Rational Drug Design
ELOVL6 is a key enzyme in long-chain fatty acid elongation, catalyzing the conversion of C16 fatty acids into C18 fatty acids. While its role in lipid metabolism is well established, recent studies have linked ELOVL6 to metabolic and neurodegenerative diseases, making it an attractive therapeutic target. However, the absence of a resolved crystal structure and limited mechanistic understanding of its inhibition pose significant challenges for drug discovery. In this study, we employ a multi-tiered computational approach, including structure prediction, molecular dynamics (MD) simulations, and free energy calculations, to investigate the structural basis of ELOVL6 function and inhibition. We identify the most thermodynamically favorable substrate binding pathway and characterize key conformational changes associated with ligand binding. By analyzing potential inhibitor binding pockets, we determine that known inhibitors preferentially target the active site, and we validate their binding affinities against experimental data. Additionally, by comparing ELOVL6 with homologous elongases, we pinpoint potentially key amino acid residues responsible for selectivity, providing insights that could guide structure-based drug design. Our findings establish a mechanistic framework for rational inhibitor development, offering a foundation for future efforts in optimizing ELOVL6-targeting therapeutics.
Open AccessComputational Analysis of ELOVL6 Structure and Inhibition for Rational Drug Design
ELOVL6 is a key enzyme in long-chain fatty acid elongation, catalyzing the conversion of C16 fatty acids into C18 fatty acids. While its role in lipid metabolism is well established, recent studies have linked ELOVL6 to metabolic and neurodegenerative diseases, making it an attractive therapeutic target. However, the absence of a resolved crystal structure and limited mechanistic understanding of its inhibition pose significant challenges for drug discovery. In this study, we employ a multi-tiered computational approach, including structure prediction, molecular dynamics (MD) simulations, and free energy calculations, to investigate the structural basis of ELOVL6 function and inhibition. We identify the most thermodynamically favorable substrate binding pathway and characterize key conformational changes associated with ligand binding. By analyzing potential inhibitor binding pockets, we determine that known inhibitors preferentially target the active site, and we validate their binding affinities against experimental data. Additionally, by comparing ELOVL6 with homologous elongases, we pinpoint potentially key amino acid residues responsible for selectivity, providing insights that could guide structure-based drug design. Our findings establish a mechanistic framework for rational inhibitor development, offering a foundation for future efforts in optimizing ELOVL6-targeting therapeutics.
- Open Access
- 13 February 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (11) , 2466-2486
Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons, characterized by dysregulated Ca2+ influx and buffering in early ALS‐affected motor neurones. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca2+, as a therapeutic target.Experimental Approach: A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the superoxide dismutase 1 (SOD1)G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy, including electrophysiology, histopathology, neuromuscular function and survival.Key Results: Among the novel FKBP12 ligands, MP‐010 was chosen for its central nervous system availability and favourable in vitro pharmaco‐toxicological profile. Chronic administration of MP‐010 to SOD1G93A mice produced preservation of motor nerve conduction, with the 61‐mg·kg−1 dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates and significant preservation of motor neurones in the spinal cord of treated mice. Notably, MP‐010 treatment significantly extended lifespan by an average of 10 days compared to vehicle.Conclusions and Implications: FKBP12 ligands, particularly MP‐010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.
- 13 February 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (11) , 2466-2486
Open AccessNovel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons, characterized by dysregulated Ca2+ influx and buffering in early ALS‐affected motor neurones. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca2+, as a therapeutic target.Experimental Approach: A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the superoxide dismutase 1 (SOD1)G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy, including electrophysiology, histopathology, neuromuscular function and survival.Key Results: Among the novel FKBP12 ligands, MP‐010 was chosen for its central nervous system availability and favourable in vitro pharmaco‐toxicological profile. Chronic administration of MP‐010 to SOD1G93A mice produced preservation of motor nerve conduction, with the 61‐mg·kg−1 dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates and significant preservation of motor neurones in the spinal cord of treated mice. Notably, MP‐010 treatment significantly extended lifespan by an average of 10 days compared to vehicle.Conclusions and Implications: FKBP12 ligands, particularly MP‐010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.
- Open Access
- 9 March 2024
- Published by Wiley
Novel FKBP12 ligand promotes functional improvement in SOD1G93A ALS mice
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons (MNs), characterized by dysregulated Ca2+ influx and buffering in early ALS-affected MNs. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca2+, as a therapeutic target. Experimental Approach: A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the SOD1G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy including electrophysiology, histopathology, neuromuscular function, and survival. Key Results: Among the novel FKBP12 ligands, MP-010 was chosen for its central nervous system availability. Chronic administration of MP-010 to SOD1G93A mice produced a dose-dependent preservation of motor nerve conduction, with the 61 mg/kg dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates, and significant preservation of MNs in the spinal cord of treated mice. Notably, MP-010 treatment significantly extended lifespan by an average of 10 days compared to vehicle. Conclusions and Implications: FKBP12 ligands, particularly MP-010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.
- 9 March 2024
- Published by Wiley
Open AccessNovel FKBP12 ligand promotes functional improvement in SOD1G93A ALS mice
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons (MNs), characterized by dysregulated Ca2+ influx and buffering in early ALS-affected MNs. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca2+, as a therapeutic target. Experimental Approach: A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the SOD1G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy including electrophysiology, histopathology, neuromuscular function, and survival. Key Results: Among the novel FKBP12 ligands, MP-010 was chosen for its central nervous system availability. Chronic administration of MP-010 to SOD1G93A mice produced a dose-dependent preservation of motor nerve conduction, with the 61 mg/kg dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates, and significant preservation of MNs in the spinal cord of treated mice. Notably, MP-010 treatment significantly extended lifespan by an average of 10 days compared to vehicle. Conclusions and Implications: FKBP12 ligands, particularly MP-010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.
- Open Access
Lipid Dysregulation Unveil the Intricate Interplay of Lysosomal and Mitochondrial Changes in Frontotemporal Dementia with GRN Haploinsufficiency
This study investigates the cellular pathology resulting from haploinsufficiency of progranulin (PGRN) in frontotemporal dementia (FTD) associated with granulin (GRN) mutations. Utilizing fibroblasts from FTD patients carrying a distinctive GRN mutation (c.709-1G>A), we observed lysosomal and lipofuscin accumulation, impaired lysosomal function, compromised autophagic flux, and mitochondrial abnormalities. Notably, recombinant human progranulin (rhPGRN) treatment restored lysosomal acidification, mitigated mitochondrial defects, and demonstrated beneficial effects. FTD-GRN fibroblasts exhibited abnormal lipid metabolism with increased lipid droplet formation, influenced by GRN haploinsufficiency and modulated by rhPGRN. Under nutrient-rich conditions, lipid droplet dynamics were shaped by autophagy and mitochondrial processes, potentially due to impaired fatty acid oxidation. These findings highlight a direct association between GRN deficiency and altered lysosomal-mitochondrial interactions, influencing lipid metabolism and contributing to FTD pathogenesis. The documented lysosomal dysfunction, impaired autophagy, mitochondrial anomalies, and altered lipid metabolism collectively suggest a complex interplay of cellular processes in the development of FTD-GRN.
Open AccessLipid Dysregulation Unveil the Intricate Interplay of Lysosomal and Mitochondrial Changes in Frontotemporal Dementia with GRN Haploinsufficiency
This study investigates the cellular pathology resulting from haploinsufficiency of progranulin (PGRN) in frontotemporal dementia (FTD) associated with granulin (GRN) mutations. Utilizing fibroblasts from FTD patients carrying a distinctive GRN mutation (c.709-1G>A), we observed lysosomal and lipofuscin accumulation, impaired lysosomal function, compromised autophagic flux, and mitochondrial abnormalities. Notably, recombinant human progranulin (rhPGRN) treatment restored lysosomal acidification, mitigated mitochondrial defects, and demonstrated beneficial effects. FTD-GRN fibroblasts exhibited abnormal lipid metabolism with increased lipid droplet formation, influenced by GRN haploinsufficiency and modulated by rhPGRN. Under nutrient-rich conditions, lipid droplet dynamics were shaped by autophagy and mitochondrial processes, potentially due to impaired fatty acid oxidation. These findings highlight a direct association between GRN deficiency and altered lysosomal-mitochondrial interactions, influencing lipid metabolism and contributing to FTD pathogenesis. The documented lysosomal dysfunction, impaired autophagy, mitochondrial anomalies, and altered lipid metabolism collectively suggest a complex interplay of cellular processes in the development of FTD-GRN.